← Back to All US Stocks

BiomX Inc. (PHGE) Fundamental Analysis & AI Grade 2026

PHGE NYSE Biological Products, (No Diagnostic Substances) DE CIK: 0001739174
Recently Updated • Analysis: May 23, 2026 • SEC Data: 2026-03-31
Combined AI Grade
D
88% Confidence
N/A
D
88% Conf
Pending
Analysis scheduled

📊 PHGE Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: $-5.4M
Current Ratio: 1.24x
Debt/Equity: N/A
EPS: $7.38
AI Grade: D with 88% confidence
BiomX Inc. (PHGE) receives a D fundamental grade with 88% confidence from our AI analysis based on SEC 10-K filings. Below is our complete PHGE stock analysis for 2026.

Is BiomX Inc. (PHGE) a Good Investment?

Claude

BiomX is in severe financial distress with negative stockholders equity (-$881K), indicating liabilities exceed assets, coupled with negative operating cash flow (-$5.4M) that cannot service $11.2M in long-term debt. The company appears to have little to no revenue while burning significant cash, leaving approximately 2-3 months of runway at current burn rate.

BiomX Inc. Key Strengths (PHGE)

Claude
  • + Minimal capital expenditure ($2K) reduces cash drain from expansion
  • + Current ratio of 1.24x provides marginal short-term liquidity coverage
  • + Small asset base ($3.3M) limits downside exposure

PHGE Stock Risks: BiomX Inc. Investment Risks

Claude
  • ! Negative stockholders equity indicates technical insolvency from balance sheet perspective
  • ! Operating cash flow of -$5.4M with only $1.2M cash creates imminent liquidity crisis within months
  • ! Long-term debt of $11.2M cannot be serviced; negative interest coverage of -1.5x
  • ! Absence of revenue data suggests pre-revenue or failed commercialization
  • ! ROA of -588.7% reflects severe asset inefficiency and value destruction

Key Metrics to Watch

Claude
  • * Cash burn rate and months of cash runway remaining
  • * Revenue generation or announcement of significant capital infusion
  • * Restructuring announcements or debt refinancing negotiations

BiomX Inc. (PHGE) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
$-19.1M
EPS (Diluted)
$7.38
Free Cash Flow
$-5.4M
Total Assets
$3.3M
Cash Position
$1.2M

💡 AI Analyst Insight

BiomX Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

PHGE Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -588.7%
FCF Margin N/A

PHGE vs Healthcare Sector: How BiomX Inc. Compares

How BiomX Inc. compares to Healthcare sector averages

Net Margin
PHGE 0.0%
vs
Sector Avg 12.0%
PHGE Sector
ROE
PHGE 0.0%
vs
Sector Avg 15.0%
PHGE Sector
Current Ratio
PHGE 1.2x
vs
Sector Avg 2.0x
PHGE Sector
Debt/Equity
PHGE 0.0x
vs
Sector Avg 0.6x
PHGE Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is BiomX Inc. Stock Overvalued? PHGE Valuation Analysis 2026

Based on fundamental analysis, BiomX Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

BiomX Inc. Balance Sheet: PHGE Debt, Cash & Liquidity

Current Ratio
1.24x
Quick Ratio
1.24x
Debt/Equity
N/A
Debt/Assets
127.1%
Interest Coverage
-1.52x
Long-term Debt
$11.2M

PHGE Revenue & Earnings Growth: 5-Year Financial Trend

PHGE 5-year financial data:
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: BiomX Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $58.31 reflects profitable operations.

PHGE Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

BiomX Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$5.4M
Cash generated from operations
Capital Expenditures
$2.0K
Investment in assets
Dividends
None
No dividend program

PHGE SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for BiomX Inc. (CIK: 0001739174)

📋 Recent SEC Filings

Date Form Document Action
May 28, 2026 8-K ea0292479-8k_biomx.htm View →
May 20, 2026 10-Q ea0291120-10q_biomxinc.htm View →
May 5, 2026 8-K ea0289209-8k_biomx.htm View →
Apr 30, 2026 10-K/A ea0288312-10ka1_biomx.htm View →
Apr 16, 2026 8-K ea028664701-8k_biomx.htm View →

Frequently Asked Questions about PHGE

What is the AI rating for PHGE?

BiomX Inc. (PHGE) has an AI grade of D with 88% confidence, based on fundamental analysis of SEC EDGAR filings.

What are PHGE's key strengths?

Claude: Minimal capital expenditure ($2K) reduces cash drain from expansion. Current ratio of 1.24x provides marginal short-term liquidity coverage.

What are the risks of investing in PHGE?

Claude: Negative stockholders equity indicates technical insolvency from balance sheet perspective. Operating cash flow of -$5.4M with only $1.2M cash creates imminent liquidity crisis within months.

What is PHGE's revenue and growth?

BiomX Inc. reported revenue of N/A.

Does PHGE pay dividends?

BiomX Inc. does not currently pay dividends.

Where can I find PHGE SEC filings?

Official SEC filings for BiomX Inc. (CIK: 0001739174) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is PHGE's EPS?

BiomX Inc. has a diluted EPS of $7.38.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is PHGE's fundamental grade?

Based on our AI fundamental analysis in May 2026, BiomX Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is PHGE stock overvalued or undervalued?

Valuation metrics for PHGE: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is PHGE's AI grade for 2026?

Our dual AI analysis gives BiomX Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is PHGE's free cash flow?

BiomX Inc.'s operating cash flow is $-5.4M, with capital expenditures of $2.0K.

How does PHGE compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 1.24 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 23, 2026 | Data as of: 2026-03-31 | Powered by Claude AI